CN100335061C - Use of stachyose in preparing drug for diabetes and its preparation method - Google Patents
Use of stachyose in preparing drug for diabetes and its preparation method Download PDFInfo
- Publication number
- CN100335061C CN100335061C CNB031450245A CN03145024A CN100335061C CN 100335061 C CN100335061 C CN 100335061C CN B031450245 A CNB031450245 A CN B031450245A CN 03145024 A CN03145024 A CN 03145024A CN 100335061 C CN100335061 C CN 100335061C
- Authority
- CN
- China
- Prior art keywords
- stachyose
- medicine
- diabetes
- treatment
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a novel medicine purpose of stachyose of a plant extraction component, namely an application in preparing medicine for treating diabetes by the stachyose. The present invention also relates to an application method for preparing the medicine for treating diabetes by the stachyose. The stachyose can be prepared into the medicine for treating diabetes, and the medicine for treating diabetes, which is prepared by using the stachyose, is traditional Chinese medicine which has the advantages of blood sugar reduction, blood lipid reduction, insulin sensitivity increase and no toxic or side effect. The active ingredient of the stachyose in the medicine for treating diabetes is shown as the chemical structural formula (formula I).
Description
Technical field the present invention relates to Chinese medicine or natural medicine field, relates to a kind of plant extract composition stachyose (stachyose) specifically and is used for the treatment of application in the medicine of diabetes in preparation.The invention still further relates to stachyose and be used for the treatment of application process in the medicine of diabetes in preparation.
Background technology is present, the patient of diabetes surpasses 1.5 hundred million people in the world, and China surpasses 3,000 ten thousand people, and sickness rate also has the trend that rises year by year, its mortality rate is only second to tumor and cardiovascular diseases in noninfectious, be the third-largest disease that jeopardizes human health.The now medicine of Chang Yong treatment diabetes such as sulfonylurea, biguanides and Alpha-glucosidase inhibitor etc., side effect is big, for example produces high galactaemia and infringement liver, kidney and hemocyte etc., loses efficacy but also can produce treatment.Though have the Chinese patent medicine of many treatment diabetes to sell on the market, drug effect is often not remarkable yet, the patient still need rely on western medicine.Therefore, the medicine of seeking good effect, treatment diabetes that toxic and side effects is little from Chinese medicine or natural plants becomes focus in recent years.
Stachyose is the native compound that extracts from Chinese medicine Radix Rehmanniae and betony etc.Stachyose uses mainly as the additive of functional food raw material and bread and cheese, has the human body intestinal canal of promotion profitable strain propagation, suppresses to suffer from diarrhoea, protects the liver, effects such as cholesterol reducing, antinutritional factor.Chinese patent application number is 98100020.7,99124982.8,00123630.X and 01109692.6 4 pieces of documents, the method that has disclosed from stachyose platymiscium such as Chinese artichoke, Rhizoma Lycopi Lucidi (or Herba Lycopi), Rhizoma Humatae Tyermanni, snail dish, cutworm etc. preparation or produced stachyose.
Present data both domestic and external shows that to the existing bibliographical information of the research of stachyose, the content that relates to is: (1) studies the chemical composition of some Chinese medicine or plant or extraction separation stachyose, assay and structure evaluation from the plant that contains stachyose; (2) absorption dynamics of the stachyose that extracts in some Chinese medicine research; (3) stachyose is to preventive effect clinical, patients with subclinical hepatic encephalopathy.But the application report of the relevant stachyose of Shang Weijian in treating diabetes up to the present.
Summary of the invention the purpose of this invention is to provide the new pharmaceutical applications of stachyose, and promptly stachyose is used for the treatment of application in the medicine of diabetes in preparation.Another object of the present invention provides stachyose and is used for the treatment of application process in the medicine of diabetes in preparation.The medicine of the treatment diabetes of this application stachyose preparation is the Chinese medicine medicine that has blood sugar lowering, blood fat reducing, increase insulin sensitivity, has no side effect.
Realize that technical scheme of the present invention is such: the application of stachyose in preparation treatment diabetes medicament, its active component of stachyose that it is characterized in that treating in the medicine of diabetes has following chemical structural formula:
The medicine of the treatment diabetes of stachyose preparation be in content of stachyose be 0.01～99.99% with pharmaceutical carrier content be that 99.99～0.01% ratio is made.
Stachyose is used for the treatment of manufacture method in the medicine of diabetes in preparation: make the medicine of forming as active ingredient and pharmaceutical carrier with stachyose of the present invention, can be according to conventional pharmaceutical methods, make clinically for oral administration or injection type of said routine in acceptable, the pharmaceutics, as tablet, capsule, powder and injection etc.
Stachyose of the present invention can be the stachyose preparation that extracts from stachyose platymiscium such as Chinese artichoke, Rhizoma Lycopi Lucidi, Rhizoma Humatae Tyermanni, snail dish, cutworm etc., and wherein stachyose purity is greater than 90%; Also can be from the Chinese medicine that contains stachyose such as Radix Rehmanniae, to extract to obtain.Preparation or produce the stachyose method from stachyose platymiscium such as Chinese artichoke, Rhizoma Lycopi Lucidi, Rhizoma Humatae Tyermanni, snail dish, cutworm etc., can number be 98100020.7,99124982.8 according to Chinese patent application, in 00123630.X and the 01109692.6 4 pieces of documents disclosed from stachyose platymiscium such as Chinese artichoke, Rhizoma Lycopi Lucidi, Rhizoma Humatae Tyermanni, snail dish, cutworm etc. preparation or the method for producing stachyose make extraction.Extracting stachyose from the Chinese medicine Radix Rehmanniae also has document openly to report, can make stachyose purity greater than 90% extract.Stachyose of the present invention also can be obtained by commercially available.Pharmaceutical carrier of the present invention is conventional pharmaceutical carrier.
Inventor's process discovers that above-mentioned stachyose pharmaceutical preparation has the effect of blood sugar lowering, blood fat reducing and increase insulin sensitivity, thereby has developed the new purposes of treatment diabetes.The present invention does not see any bibliographical information and use as yet.Stachyose composition of the present invention source is abundant, safe and reliable, has no side effect, and low price is a kind of novel blood sugar reducing preparation, has good social benefit and economic benefit.
The pharmacodynamic study result of the active ingredient stachyose of experimental example 1 treatment diabetes medicament of the present invention
1. stachyose is to the regulating action of glucose hyperglycemic rat blood glucose
1.1 experiment material is subjected to the reagent thing: Herba Stachydis Japonicae Icing Sugar (purity is greater than 90%); Animal subject: the Wistar rat, ♀, ♂ half and half, body weight 180～220g, Lanzhou medical college Experimental Animal Center provides.
1.2 method and result be animal subject Wistar rat, ♀, ♂ half and half, and body weight 180～220g is divided into 3 groups at random, and every group of 8-10 only is respectively normal control group, glucose hyperglycemia matched group and stachyose administration group.Normal control group and glucose hyperglycemia matched group distilled water are irritated stomach, once a day, and continuous 7 days; Stachyose administration group gives stachyose 200mg/kg and irritates stomach, once a day, and continuous 7 days.After the last administration, fasting 7h, blood glucose value (0 minute) is measured in eyeball rear vein beard blood sampling, lumbar injection glucose solution (2.5g/kg) afterwards, the blood glucose value of giving behind the glucose 30 minutes, 60 minutes and 120 minutes is measured in the blood sampling of eyeball rear vein beard.The result is with the t of two groups of means check and see Table 1.
1.3 discuss: the fasting glucose there was no significant difference of (0 minute) each group before the injection.30 minutes, 60 minutes and 120 minutes blood sugar concentration in the glucose tolerance test have significance to reduce in the stachyose group than glucose hyperglycemia matched group.The expression stachyose can reduce the glucose hyperglycemia.
Table 1 stachyose is to the influence of glucose hyperglycemic rat blood sugar level
| Group | Dosage (mg/g) | Blood glucose value (mg/dl) | |||
| 0 minute | 30 minutes | 60 minutes | 120 minutes | ||
| Normal control glucose contrast glucose+stachyose | 0 0 200 | 89.4±15.4 90.6±19.3 88.7±17.8 | 87.8±21.5 185.6±7.2 *** 121.5±28.0 ## | 89.6±20.4 144.2±12.9 *** 122.8±26.2 # | 95.4±22.5 152.6±18.7 *** 130.4±29.2 |
x±SD，n＝8-10。
* *P＜0.001, vs normal control group;
#P＜0.05,
##P＜0.01, vs glucose hyperglycemia matched group.
2. stachyose is to the regulating action of adrenal gland's disposition hyperglycemic rat blood glucose
2.1 experiment material is subjected to the reagent thing: Herba Stachydis Japonicae Icing Sugar (purity is greater than 90%); Animal subject: the Wistar rat, ♀, ♂ half and half, body weight 180～220g is provided by Lanzhou medical college Experimental Animal Center.
2.2 method and result be animal subject Wistar rat, ♀, ♂ half and half, and body weight 180～220g is divided into 3 groups at random, and every group of 8-10 only is respectively normal control group, adrenal gland's disposition hyperglycemia matched group, stachyose administration group.Normal control group and adrenal gland's disposition hyperglycemia matched group distilled water are irritated stomach, once a day, and continuous 7 days; Stachyose administration group gives stachyose 200mg/kg and irritates stomach, once a day, and continuous 7 days.After the last administration, fasting 7h, blood glucose value (0 minute) is measured in eyeball rear vein beard blood sampling, subcutaneous injection epinephrine (300 μ g/kg) afterwards, the blood sampling of eyeball rear vein beard is measured and is given behind the epinephrine 30 minutes, 90 minutes blood glucose value.The result is with the t of two groups of means check and see Table 2.
2.3 discuss: the fasting glucose there was no significant difference of (0 minute) each group before the injection.30 minutes, 60 minutes and 120 minutes blood sugar concentration in the test of epinephrine hyperglycemia have significance to reduce in the stachyose group than glucose hyperglycemia matched group.The expression stachyose can reduce adrenal gland's disposition hyperglycemia.
Table 2 stachyose is to the influence of adrenal gland's disposition hyperglycemic rat blood sugar level
| Group | Dosage (mg/kg) | Blood glucose value (mg/dl) | ||
| 0 minute | 30 minutes | 90 minutes | ||
| Normal control epinephrine contrast epinephrine+stachyose | 0 0 200 | 98.2±7.4 96.0±4.9 94.5±7.1 | 100.3±15.2 313.9±50.6 *** 256.8±42.5 # | 99.8±10.7 303.2±59.4 *** 201.3±41.6 # |
x±SD，n＝8-10。,
* *P＜0.001vs normal control group;
#P＜0.05vs adrenal gland disposition hyperglycemia matched group.
3. stachyose is to the adjusting of alloxan diabetes rats blood glucose, blood fat and plasma insulin
3.1 experiment material is subjected to the reagent thing: Herba Stachydis Japonicae Icing Sugar (purity is greater than 90%); Animal subject: the Wistar rat, ♀, ♂ half and half, body weight 180～220g is provided by Lanzhou medical college Experimental Animal Center.
3.2 method and result cause the rat diabetes model with alloxan.With the dosage once abdominal cavity injection of alloxan 150mg/kg, injection alloxan fasting 10h after 3 days, the blood sampling of eyeball rear vein beard selects the rat of fasting plasma blood glucose value more than 250mg/dl to be defined as diabetes rat.Normal control group, diabetic model group, diabetes model+stachyose group and diabetes model+metformin matched group are established in experiment.Normal control group and diabetic model group are irritated stomach and are only given normal saline 2.0ml/, and the stachyose group is pressed 200mg/kg dosage and irritated stomach, and the metformin matched group is irritated stomach with metformin 500mg/kg.Below respectively organize equal successive administration 7 days.After finishing the course of treatment, fasting 10h, blood glucose, plasma insulin, plasma cholesterol, triglyceride and HDL-C are measured in the blood sampling of eye socket venous sinus.The results are shown in Table 3, table 4.
3.3 discuss: stachyose group treatment back fasting glucose reduces than the diabetic model group significance, and treatment back fasting plasma insulin increases than the diabetic model group significance.The expression stachyose can reduce the blood glucose value under the diabetic disease states and increase plasma insulin level.In addition, stachyose treatment back cholesterol, triglyceride all have obvious reduction, and treatment back HDL-C significantly raises.Illustrate that stachyose also can improve the hyperlipidemia state of diabetes rat.
Table 3 stachyose is to the influence of alloxan diabetes rats blood glucose, plasma insulin
| Group | Dosage (mg/kg) | Blood glucose value (mg/dl) | Plasma insulin (mIU/L) |
| Normal control diabetes model diabetes+stachyose diabetes+metformin | 0 0 200 500 | 94.4±16.9 390.6±59.3 *** 150.1±34.2 ## 96.8±25.2 ## | 13.3±5.9 4.2±1.2 *** 8.2±2.6 # 11.2±3.2 ## |
x±SD，n＝8-10。
* *P＜0.001vs normal control group;
#P＜0.05,
##P＜0.01vs diabetic model group.
Table 4 stachyose is to the influence of three of alloxan diabetes rats blood fat
| Group | Dosage (mg/kg) | Cholesterol (mg/dl) | Triglyceride (mg/dl) | High density lipoprotein (mg/dl) |
| Normal control diabetes model diabetes+stachyose diabetes+metformin | 0 0 200 500 | 94.4±16.9 190.6±29.3 *** 130.1±34.2 # 112.6±26.3 ## | 37.1±4.8 355.3±65.8 *** 146.7±32.3 ### 99.5±21.7 ### | 13.3±5.9 4.2±1.2 ** 10.2±2.6 ## 13.5±3.8 ## |
x±SD，n＝8-10。
*P＜0.01,
* *P＜0.001vs normal control group:
#P＜0.05,
##P＜0.01,
###P＜0.001vs diabetic model group.
The acute oral toxicity result of the test of experimental example 2 stachyose
1. experiment material is subjected to the reagent thing: Herba Stachydis Japonicae Icing Sugar (purity is greater than 90%).Animal: Kunming kind white mice, body weight 18～22g, female, hero half and half is provided by Lanzhou medical college Experimental Animal Center.
2. the shared Kunming of method and result kind white mice is 40, is divided into 4 groups at random: normal control group and stachyose administration group (three dosage groups), 10 every group, female, hero half and half.Three dosage groups of stachyose are: 5g/kg, 10g/kg and 20g/kg are equivalent to 125 times, 250 times and 500 times of clinical adult's every day of oral 3g (being dosage 0.04g/kg every day) respectively.Tried the thing dissolved in distilled water, irritated stomach by every mice 0.5ml.Matched group is irritated the distilled water of stomach equivalent.Observed 14 days, each dosage group white mice of stachyose all survives as a result, and is movable normal, do not see the toxic reaction, shows that stachyose belongs to safety non-toxic class material.It is 20g/kg that the white mice of stachyose is once irritated stomach maximum dosage-feeding (dosis tolerata).
The Preliminary Clinical Observation of experimental example 3 stachyose treatment type 2 diabetes mellitus
2002 7 with month in March, 2003, stachyose treatment type 2 diabetes mellitus is carried out clinical observation on the therapeutic effect, it is existing that stachyose is treated the observation of curative effect brief summary of 30 routine type 2 diabetes mellitus is as follows:
1 materials and methods
1.1 object choice
Diagnostic criteria: (1) tcm diagnosis standard: with reference to the dialectical standard of syndrome of deficiency of both qi and yin in " the clinical research guideline of Chinese medicine (new drug) treatment diabetes (diabetes) ".
Western medicine diagnose standard: adopt the type 2 diabetes mellitus diagnostic criteria that The World Health Organization (WHO) determined in 1999.
Case is selected: all trainings that meets the type 2 diabetes mellitus of above-mentioned Chinese and western medicine diagnostic criteria regularly go to a doctor patient and inpatient, all can include the observation case in.
Exclusion standard: (1) patient before medication/suddenly blood glucose is higher than normally, by diet control, increase activity etc., fasting glucose＜7.8mmol/L or 2h blood glucose＜11.1mmol/L after the meal.(2) age is under-18s or gestation and women breast-feeding their children, and to this medicine incompatibility person.(3) can not cooperate diet control or the medication person of affecting the treatment in accordance with regulations not.(4) severe cardiac Liver and kidney complication or merge other serious primary diseases, psychotic is arranged.(5) in nearly 1 month diabetes ketosis, ketoacidosis and the infected are arranged.(6) therapy discontinued less than the regulation observation period can't be judged the infull person of curative effect or data.
The training that is diagnosed as type 2 diabetes mellitus through clinical and lab testing regularly go to a doctor patient and inpatient, through simple Diet Therapy of 1 week, hyperglycemia state is failed the effector and is the object of observation.
1.2 clinical data
Stachyose treatment group type 2 diabetes mellitus patient 30 examples, male's 16 examples wherein, women's 14 examples, 36～72 years old age, 57.7 ± 9.7 years old mean age (x ± SD, down with), course of disease two weeks～20 year, average 3.8 ± 1.1 years.Fasting glucose＜8.3mmol/L person's 10 examples, 8.4-11.1mmol/L person's 30 examples,＞11.2mmol/L person 10 examples.The routine number that merges hyperlipidemia, coronary heart disease, peripheral neuropathy is respectively 14,2,4 examples.Chinese medicine (JINQI JIANGTANG PIAN) matched group 20 examples, male's 12 examples wherein, women's 8 examples, 31～82 years old age, 57.3 ± 10.1 years old mean age, course of disease February～15 year, average 4.0 ± 1.2 years, fasting glucose＜8.3mmol/L person's 5 examples, 8.4-11.1mmol/L person's 12 examples,＞11.2mmol/L person 3 examples.The routine number that merges hyperlipidemia, coronary heart disease, peripheral neuropathy is respectively 8,3,2 examples.Two groups of case sources, sex, age and course of disease analyses do not have obvious significant difference (P＞0.05).
1.3 Therapeutic Method
1.3.1 stachyose group: give the stachyose group after diagnosis is clear and definite and give stachyose (purity is greater than 90%) 1.0g, tid, clothes, and other oral antidiabetic drug of stopping using before the meal.Instruct patient's diet control and physical training in the therapeutic process.Being a course of treatment January, 2～3 courses of treatment of overview.
1.3.2 Chinese medicine matched group: give JINQI JIANGTANG PIAN after diagnosis is clear and definite, 7 (every 0.3g), tid, clothes, and other oral antidiabetic drug of stopping using before the meal.Instruct patient's diet control and physical training in the therapeutic process.Being a course of treatment January, 2～3 courses of treatment of overview.
1.4 observation index and method
All make fasting glucose (FBG), 2 hours after the meal blood glucose (PBG) before and after observing treatment.The observation that hematuria conventional sense and clinical main symptom change.Some cases has been done the detection of plasma insulin (IRI) and blood fat (cholesterol TC, glycerol triplet TG, HDL-C HDL-C).
1.5 criterion of therapeutical effect
According to the curative effect judging standard in " the clinical research guideline of Chinese medicine (new drug) treatment diabetes (diabetes) " of Ministry of Public Health promulgation in 1993.Produce effects: treatment back symptom disappears substantially, fasting glucose＜7.2mol/L, 2h blood glucose＜8.3mmol/L after the meal, twenty-four-hour urine sugar quantitatively＜10g or blood glucose 24h glucose in urine be quantitatively than descending more than 30% before the treatment; Effectively: treatment back symptom is obviously improved, fasting glucose＜8.3mmol/L, the glucose in urine of 2h blood glucose＜10.0mmol/L, or 24h after the meal quantitatively＜25.0g, or blood glucose, 24h glucose in urine quantitatively descend more than 10% before the treatment.Invalid: treatment back symptom does not have obvious improvement, and blood glucose, glucose in urine descend and do not reach effective standard.
1.6 statistical method
Adopt SPSS software to carry out statistical analysis, the treatment front and back are relatively checked with the t of own control mean relatively on the same group.
2 results
2.1 clinical efficacy: stachyose treatment is to type 2 diabetes mellitus patient's therapeutic effect: produce effects 11 examples, and effective 15, invalid 4 examples.Total effective rate 86%.JINQI JIANGTANG PIAN group therapeutic effect: produce effects 14 examples, effective 2, invalid 4 examples, total effective rate 80%.
2.2 clinical symptoms: symptoms such as stachyose group treatment back polydipsia, polyphagia, polyuria and spiritlessness and weakness, the soreness of waist, few clothes all have clear improvement.
2.3 stachyose is to the influence of type 2 diabetes mellitus patient blood glucose and plasma insulin: see Table 5.
As seen from Table 5, stachyose treatment back fasting glucose and after the meal 2h blood glucose with treat before compare, decline is all arranged, there was a significant difference (P＜0.05).
2.3 stachyose is to the influence of type 2 diabetes mellitus patient blood fat: see Table 6.
As seen from Table 6, TC and TG difference also have significance (P＜0.05) before and after the stachyose treatment.HDL-C does not then have significance and changes.
2.4 side effect
The stachyose group there is no reactions such as diarrhoea, stomachache, vomiting, drug eruption and hypoglycemia.
Table 5 stachyose is to type 2 diabetes mellitus patient fasting glucose, the influence of 2h blood glucose and plasma insulin after the meal
| Group | The example number | Fasting glucose (mmol/L) | 2h blood glucose (mmol/L) after the meal | Plasma insulin (mIU/L) | |||
| Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Stachyose group Chinese medicine matched group | 30 20 | 10.18±2.48 10.50±2.36 | 7.39±1.29* 8.56±1.54* | 15.45±4.23 15.66±5.06 | 12.80±3.35* 13.10±3.63* | 13.71±4.46 13.03±4.51 | 13.56±1.94 13.56±1.85 |
Annotate:
*P＜0.05, relatively preceding with treatment.x±SD。
Table 6 stachyose is to the influence (mmol/L) of type 2 diabetes mellitus patient plasma cholesterol, triglyceride and high density lipoprotein
| Group | The example number | Cholesterol | Triglyceride | High density lipoprotein | |||
| Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Stachyose group Chinese medicine matched group | 30 20 | 6.59±0.87 6.65±1.10 | 4.66±0.55* 5.39±0.59* | 2.06±0.47 2.12±0.60 | 1.67±0.18* 1.80±0.35* | 1.18±0.26 1.21±0.33 | 1.38±0.20 1.32±0.23 |
Annotate:
*P＜0.05, relatively preceding with treatment.x±SD。
3 conclusions
By stachyose treatment type 2 diabetes mellitus 30 routine clinical observation result are shown that stachyose has following outstanding feature: (1) stachyose truly has curative effect, treatment effective percentage to type 2 diabetes mellitus is 86%, and senile diabetes (fasting glucose is about 7～9mmol/L) patient's blood glucose is generally being reduced to normally about a course of treatment after the medication; Middle and high diabetes mellitus type (general two to three purposes that can reach blood sugar control the course of treatment of medication of blood glucose＞10mmol/L).(2) invalid patient had effect to stachyose to using Western medicine antidiabetic drug such as metformin, sulphanylureas etc., also can play a role with the Western medicine antidiabetic drug is collaborative, and curative effect is more singly with for well; (3) observe the characteristics that stachyose has increases patient's insulin sensitivity clinically.(4) stachyose has reduction effect preferably for hyperlipidemia except blood sugar lowering, and this also is a distinguishing feature of stachyose.(5) up to the present, do not find that stachyose has apparent side effect, this is significantly to be different from the Western medicine antidiabetic drug.
The specific embodiment
Embodiment 1 preparation stachyose tablet
Raw material: stachyose (purity＞90%) 1000g
Sodium Hydroxymethyl Stalcs 40g
Starch 50g
Magnesium stearate 10g
Water is an amount of
Method for making: water intaking threose 1000g is ground into fine powder, and it is standby to cross 100 mesh sieves.Starch 50g decocts with water and makes 5% starch slurry solution for standby.With stachyose fine powder and 1/2 recipe quantity Sodium Hydroxymethyl Stalcs mix homogeneously, add 5% starch slurry solution system soft material, to cross 18 mesh sieves and granulate, 18 mesh sieve granulate are crossed in 60 ℃ of aeration-dryings, add remaining Sodium Hydroxymethyl Stalcs, magnesium stearate mixing, tabletting, the heavy 0.55g of sheet.
Embodiment 2 preparation stachyose capsules
Raw material: stachyose (purity＞90%)
Method for making: the water intaking threose is ground into fine powder, crosses sieve No. 6, the hard capsule of packing into No. 0, every loading amount 0.4g.
Embodiment 3 preparation stachyose powders
Raw material: stachyose (purity＞90%)
Method for making: the water intaking threose is ground into the fine powder that can cross No. 6 sieves, promptly.
Embodiment 4 preparation stachyose injections
The every 1ml of this product is equivalent to stachyose 0.1g.
Raw material: stachyose (purity＞90%) 100g
Sodium chloride for injection 9g
Water for injection is an amount of
Make 1000ml
Method for making: water intaking threose fine powder 100g, add water and stir into solution, adding distil water decocted 2 hours to 800ml again, filtered.Filtrate adds 95% ethanol makes that to contain alcohol amount be 65%, heat a little in water-bath.Reclaim the ethanol in the filtrate, concentrated filtrate adds people's sodium chloride for injection to 400ml, and dissolving adds the injection water to 1000ml, be filtered to clear and bright, embedding, flowing steam sterilization 30 minutes, promptly.
The above embodiments are to application and the further specifying of application process thereof of stachyose of the present invention in preparation treatment diabetes medicament; but this does not also mean that limitation of the present invention; any application stachyose all should belong to protection scope of the present invention as each quasi drugs of preparation treatment diabetes medicament component.
Claims (2)
1, the application of stachyose in preparation treatment diabetes medicament is characterized in that the stachyose active component in the medicine of treatment diabetes has following chemical structural formula:
2, the application of stachyose as claimed in claim 1 in preparation treatment diabetes medicament is characterized in that: the medicine of described treatment diabetes be in content of stachyose be 0.01～99.99% with pharmaceutical carrier content be that 99.99～0.01% ratio is made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031450245A CN100335061C (en) | 2003-06-19 | 2003-06-19 | Use of stachyose in preparing drug for diabetes and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031450245A CN100335061C (en) | 2003-06-19 | 2003-06-19 | Use of stachyose in preparing drug for diabetes and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1565461A CN1565461A (en) | 2005-01-19 |
| CN100335061C true CN100335061C (en) | 2007-09-05 |
Family
ID=34471332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031450245A Expired - Fee Related CN100335061C (en) | 2003-06-19 | 2003-06-19 | Use of stachyose in preparing drug for diabetes and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100335061C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114225043A (en) * | 2021-12-31 | 2022-03-25 | 江南大学 | Application of stachyose modified substance in preparation of medicine for treating castration-resistant prostate cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1223265A (en) * | 1998-01-12 | 1999-07-21 | 济南三株药业有限公司 | Process for preparing stachyose and its products and application |
| CN1300857A (en) * | 1999-12-23 | 2001-06-27 | 中国食品发酵工业研究所 | Stachyose and its preparing process |
-
2003
- 2003-06-19 CN CNB031450245A patent/CN100335061C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1223265A (en) * | 1998-01-12 | 1999-07-21 | 济南三株药业有限公司 | Process for preparing stachyose and its products and application |
| CN1300857A (en) * | 1999-12-23 | 2001-06-27 | 中国食品发酵工业研究所 | Stachyose and its preparing process |
Non-Patent Citations (1)
| Title |
|---|
| 水苏糖 袁其朋等，精细与专用化学品，第1期 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1565461A (en) | 2005-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1298363C (en) | Health product for assisting blood sugar-decreasing function and its preparation method | |
| CN101607006B (en) | Application of Chinese medicinal composition in preparing medicament for treating hypertension | |
| CN101033245A (en) | Preparation method and application of pedunculoside | |
| CN101045088A (en) | Medicine composition for treating diabetes and its preparing method | |
| CN1137900C (en) | Extracting process and application of polygonapolyose | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1813819A (en) | Hedgehog hydnum fruiting body or hyphostroma and culture extract and formulation and preparing method | |
| CN101829271B (en) | Chinese medicinal compound with function of treating diabetes and preparation method and application thereof | |
| CN100335061C (en) | Use of stachyose in preparing drug for diabetes and its preparation method | |
| CN1065753C (en) | Hypoglycemic instant powder and prepn. method | |
| CN101264203B (en) | Chinese and western medicine composition for treating diabetes | |
| CN1742879A (en) | Chinese medicine for reducing blood sugar and preparation thereof | |
| CN1733089A (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN100337665C (en) | Oral medicine for treating diabetes | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1778311A (en) | Polysaccharid glucoside Chinese medicinal oral preparation and its making method thereof | |
| CN1857368A (en) | Medicine composition for treating diabetes | |
| CN1265805C (en) | Chinese medicine oral preparation for lonering blood sugar and its preparation method | |
| CN1287838C (en) | Medicine for treating diabetes | |
| CN1548142A (en) | Medicine for improving sugar tolerance and treating diabetes and its prepn process | |
| CN1927289A (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and its preparation | |
| CN1748771A (en) | Chinese medicine composition for treating diabetes and its preparing method and use | |
| CN102293817B (en) | Traditional Chinese medicine composition for reducing blood sugar and preparation method thereof | |
| CN1201742C (en) | Hypoglycemic health-care food for diabetes type II; | |
| CN1197585C (en) | Application of polygonatum polyscaccharide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG RUXUE Free format text: FORMER OWNER: CHEN YING; APPLICANT Effective date: 20070105 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070105 Address after: 730050, room 18, building 98, 202 West West Lake street, Qilihe District, Gansu, Lanzhou Applicant after: Zhang Ruxue Address before: 730030 No. 401, Lane 19, Chengguan District, Chengguan District, Gansu, Lanzhou Applicant before: Chen Ying Co-applicant before: Wang Huiyun |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070905 Termination date: 20110619 |